Medical Costs Associated with High/Moderate/Low Likelihood of Adult Growth Hormone Deficiency: A Healthcare Claims Database Analysis.

IF 2.1 Q3 HEALTH CARE SCIENCES & SERVICES ClinicoEconomics and Outcomes Research Pub Date : 2024-03-08 eCollection Date: 2024-01-01 DOI:10.2147/CEOR.S445495
Kevin C J Yuen, Lewis S Blevins, David R Clemmons, Mads Faurby, Andrew R Hoffman, Nicky Kelepouris, Janice M Kerr, Jens Magelund Tarp, Maria Fleseriu
{"title":"Medical Costs Associated with High/Moderate/Low Likelihood of Adult Growth Hormone Deficiency: A Healthcare Claims Database Analysis.","authors":"Kevin C J Yuen, Lewis S Blevins, David R Clemmons, Mads Faurby, Andrew R Hoffman, Nicky Kelepouris, Janice M Kerr, Jens Magelund Tarp, Maria Fleseriu","doi":"10.2147/CEOR.S445495","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Adult growth hormone deficiency (AGHD) is often underdiagnosed and undertreated, leading to costly comorbidities. Previously, we developed an algorithm to identify individuals in a commercially insured US population with high, moderate, or low likelihood of having AGHD. Here, we estimate and compare direct medical costs by likelihood level.</p><p><strong>Patients and methods: </strong>Retrospective, observational analysis using the Truven Health MarketScan database to analyze direct medical costs relating to inpatient and outpatient claims, outpatient prescription claims, medication usage, clinical utilization records, and healthcare expenditures. Patients were categorized into groups based on algorithmically determined likelihoods of AGHD. Likelihood groups were further stratified by age and sex. Trajectories of annual costs (USD) by likelihood level were also investigated.</p><p><strong>Results: </strong>The study cohort comprised 135 million US adults (aged ≥18 years). Individuals ranked as high-likelihood AGHD had a greater burden of comorbid illness, including cardiovascular disease and diabetes, than those ranked moderate- or low-likelihood. Those in the high-likelihood group had greater mean total direct medical monthly costs ($1844.51 [95% confidence interval (CI): 1841.24;1847.78]) than those in the moderate- ($945.65 [95% CI: 945.26;946.04]) and low-likelihood groups ($459.10 [95% CI: 458.95;459.25]). Outpatient visits accounted for the majority of costs overall, although cost per visit was substantially lower than for inpatient services. Costs tended to increase with age and peaked around the time that individuals were assigned a level of AGHD likelihood. Total direct medical costs in individuals with a high likelihood of AGHD exceeded those for individuals with moderate or low likelihood.</p><p><strong>Conclusion: </strong>Understanding the trajectory of healthcare costs in AGHD may help rationalize allocation of healthcare resources.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10929649/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ClinicoEconomics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S445495","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Adult growth hormone deficiency (AGHD) is often underdiagnosed and undertreated, leading to costly comorbidities. Previously, we developed an algorithm to identify individuals in a commercially insured US population with high, moderate, or low likelihood of having AGHD. Here, we estimate and compare direct medical costs by likelihood level.

Patients and methods: Retrospective, observational analysis using the Truven Health MarketScan database to analyze direct medical costs relating to inpatient and outpatient claims, outpatient prescription claims, medication usage, clinical utilization records, and healthcare expenditures. Patients were categorized into groups based on algorithmically determined likelihoods of AGHD. Likelihood groups were further stratified by age and sex. Trajectories of annual costs (USD) by likelihood level were also investigated.

Results: The study cohort comprised 135 million US adults (aged ≥18 years). Individuals ranked as high-likelihood AGHD had a greater burden of comorbid illness, including cardiovascular disease and diabetes, than those ranked moderate- or low-likelihood. Those in the high-likelihood group had greater mean total direct medical monthly costs ($1844.51 [95% confidence interval (CI): 1841.24;1847.78]) than those in the moderate- ($945.65 [95% CI: 945.26;946.04]) and low-likelihood groups ($459.10 [95% CI: 458.95;459.25]). Outpatient visits accounted for the majority of costs overall, although cost per visit was substantially lower than for inpatient services. Costs tended to increase with age and peaked around the time that individuals were assigned a level of AGHD likelihood. Total direct medical costs in individuals with a high likelihood of AGHD exceeded those for individuals with moderate or low likelihood.

Conclusion: Understanding the trajectory of healthcare costs in AGHD may help rationalize allocation of healthcare resources.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与成人生长激素缺乏症高/中/低可能性相关的医疗费用:医疗索赔数据库分析》。
目的:成人生长激素缺乏症(AGHD)往往诊断不足、治疗不及时,导致代价高昂的并发症。此前,我们开发了一种算法,用于识别美国商业保险人群中患有 AGHD 的可能性高、中或低的个体。在此,我们按可能性水平估算并比较了直接医疗成本:使用 Truven Health MarketScan 数据库进行回顾性观察分析,分析与住院和门诊索赔、门诊处方索赔、药物使用、临床使用记录和医疗保健支出相关的直接医疗成本。根据算法确定的 AGHD 可能性将患者分为若干组。根据年龄和性别对可能性组进行进一步分层。研究还按可能性水平调查了年度费用(美元)的变化轨迹:研究对象包括 1.35 亿美国成年人(年龄≥18 岁)。与中度或低度可能性者相比,被列为高可能性AGHD者的合并症(包括心血管疾病和糖尿病)负担更重。与中度(945.65 美元 [95% CI:945.26;946.04])和低度(459.10 美元 [95% CI:458.95;459.25])组相比,高度组患者的平均每月直接医疗总费用更高(1844.51 美元 [95% 置信区间 (CI):1841.24;1847.78])。门诊费用占总费用的大部分,但每次门诊的费用远低于住院费用。费用往往随年龄增长而增加,并在个人被指定为 AGHD 可能性水平时达到峰值。AGHD可能性高的患者的直接医疗总费用超过了可能性中等或低的患者:结论:了解 AGHD 患者的医疗费用轨迹有助于合理分配医疗资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ClinicoEconomics and Outcomes Research
ClinicoEconomics and Outcomes Research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.70
自引率
0.00%
发文量
83
审稿时长
16 weeks
期刊最新文献
Development of the Cesarean Section Clinical Pathway Model: Not Examining Cesarean Section Comprehensively [Response to Letter]. Evaluating Service Satisfaction and Sustainability of the Afya Insurance Scheme in Kuwait: An Exploratory Analysis. Health Equity Considerations in Cost-Effectiveness Analysis: Insights from an Umbrella Review. Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia. Healthcare Resource Use and Costs Among Individuals with Vitiligo and Psychosocial Comorbidities: Retrospective Analysis of an Insured US Population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1